Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03022552 · ClinicalTrials.gov registry record

Heart Attack Research Program: Platelet Sub-Study (HARP)

A clinical trial of Myocardial Infarction, sponsored by NYU Langone Health.

Recruiting
Registry status
350
Enrollment target
1
Study location

NCT03022552 is a study of Myocardial Infarction that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 350 participants, below the 4,676-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03022552, a study of Myocardial Infarction, is actively recruiting participants, sponsored by NYU Langone Health.

RECRUITING
Registry status
350 participants
Enrollment target
1
Study location

Study Summary

This prospective observational cohort study, will investigate the platelet phenotype, platelet genetic composition, and role of platelets as effector cells in women and men with myocardial infarction (MINOCA or MI-CAD) and controls. This study, which will take place at NYU and Bellevue Medical Center, and participating external sites. May have concurrent enrollment with the HARP Main Imaging (NCT02914483). Additionally, a sex, group of age and race matched disease controls 'CATH-NOCA' composed of women and men with stable angina referred for cardiac catheterization, will be enrolled. Blood obtained during the initial catheterization and 2 months post-MI will be utilized for platelet testing.

Conditions Studied

Study Locations (1)

New York

  • NYU Langone Medical Center - New York

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2020-07-01
Est. Completion 2027-06-30

Sponsor

NYU Langone Health

1,164 total trials

What the Registry Record Tells You About NCT03022552

The ClinicalTrials.gov registry entry for NCT03022552 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,676-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (93% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Myocardial Infarction appearing as the primary indexed condition, and to 0 interventions.

NCT03022552 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03022552 about?

NCT03022552 is a clinical study titled "Heart Attack Research Program: Platelet Sub-Study (HARP)". This prospective observational cohort study, will investigate the platelet phenotype, platelet genetic composition, and role of platelets as effector cells in women and men with myocardial infarction (MINOCA or MI-CAD) and controls. This study, which will take place at NYU and Bellevue Medical Cente...

What is the current status of trial NCT03022552?

This trial is currently recruiting. The enrollment target is 350 participants. The study started on 2020-07-01. Estimated completion is 2027-06-30.

What conditions does trial NCT03022552 study?

This clinical trial studies the following conditions: Myocardial Infarction.

Who is sponsoring clinical trial NCT03022552?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03022552 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myocardial Infarction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.